Nagendran Sukumar

Nagendran Sukumar (President and Head of R&D) sold 200,000 shares of TSHA at $4.46 for $892,000.00

On 2026-04-10, Nagendran Sukumar sold 200,000 shares at $4.46, reducing his holdings from 1,336,410 shares to 1,136,410 shares. The current price of $4.42 is -25.2% from the 52-week high of $5.91. Across his cross-ticker track record, his 6 prior sells achieved a 90-day well-timed rate of 50.00%, though at TSHA specifically, 2 of 3 prior measurable sells were well-timed at the 90-day mark. The company is unprofitable with a net income of $-32,733,000.00 over its most recent full fiscal year, though revenue growth was positive at +17.3% year-over-year. This sale by the company's R&D leader occurs as the stock trades well below its annual peak.

Nagendran Sukumar (Pres./Head of R&D) sold 116,050 shares at avg $4.72 for $547,468.98; stock down 18.4% in 30 days post-sale.

Nagendran Sukumar, the company's President and Head of R&D, executed 2 separate sales totaling 116,050 shares for $547,468.98 on 2026-01-23 and 2026-01-26, reducing his holdings by 8.1% to 1.32M shares. The timing pattern is notable: Sukumar's prior TSHA sales on 2025-09-10, 2025-11-28, and 2025-12-01 were followed by 30-day gains ranging from +22.0% to +51.1%, suggesting his prior exits preceded further price appreciation. The current stock price is $4.76, down 18.4% over 30 days and 19.5% from its 52-week high of $5.91, indicating a sharp reversal since these January sales. The company remains unprofitable with $-32.7M net income and negative annual revenue growth of -46.1%, creating structural headwinds regardless of insider trading patterns. The divergence between Sukumar's recent timing (selling into apparent strength relative to current price weakness) and the subsequent market deterioration warrants attention.

TSHA President Nagendran Sukumar sells 200,000 shares at $4.71; stock down -12.5% in 30 days since Jan 12 sale.

Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies, sold 200,000 shares at $4.71 on 2026-01-12 for $942,000.00, reducing his holdings by 12.2% to 1,433,439 shares. At his prior two sales at this ticker (2025-12-01 and 2025-11-28), the stock rose 22.0% and 22.7% respectively over the following 30 days, but this sale has instead been followed by a -12.5% move in 30 days, indicating a reversal in the pattern observed just weeks earlier. The company remains unprofitable with $-32,733,000.00 net income in the most recent period and revenue declining 46.1% year-over-year, providing material context for executive equity decisions during ongoing operational challenges.

TSHA President Nagendran Sukumar sells 370,172 shares (370.2K shares) for $1,695,905.72 across 2 transactions at $4.75 and $4.51

Nagendran Sukumar, President and Head of R&D, executed 2 separate sales totaling 370,172 shares for $1,695,905.72, reducing his holdings by 26.9% from 1,376,611 to 1,006,439 shares. The sales occurred at $4.75 on 2025-11-28 and $4.51 on 2025-12-01, with a blended average price of $4.58, notably above the current market price of $4.43. The company faces significant operational headwinds: revenue is $0.00 for the latest quarter, net income stands at -$32,733,000.00, and annual revenue growth shows a decline of -46.1%. While Sukumar's cross-ticker track record demonstrates positive returns following his prior sells (avg 30d return +51.1%), his same-ticker history at TSHA is limited—only one prior sale on 2025-09-10 with a 30d outcome of +51.1%. The magnitude of this divestiture—removing over one-quarter of his holdings—combined with the company's deteriorating financial position and recent revenue contraction, warrants investor attention.

TSHA President Nagendran Sukumar sold 200,000 shares at $3.23 for $646,000; holds 1,006,439 shares post-sale amid unprofitable operations.

Nagendran Sukumar, President and Head of R&D, sold 200,000 shares at $3.23, reducing his holdings by 16.6% from 1.21M shares to 1.01M shares. Taysha Gene Therapies is deeply unprofitable with net income of $-26.9M and annual revenue decline of -46.1%, with latest quarterly revenue at $2.0M. The sale occurred while the stock trades at $3.07, near its 52-week high of $3.36, though the company's financial deterioration and steep revenue contraction raise questions about sustainability. An R&D leader's material stake reduction during a period of operational distress warrants investor scrutiny of pipeline progress and cash runway.